Product Portfolio & Pipeline
Product & Indication
Development Stage
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
MARKETED
TREG-BASED CELL THERAPY
TI-168 – Hemophilia A with inhibitors
▶
Myasthenia gravis
▶
Membranous nephropathy
▶
Neuromyelitis Optica
▶
NEUROMUSCULAR BLOCKING AGENTS (NMBAS)
IV intermediate-acting agent (BX-1000)
▶
IV ultrashort-acting agent (BX-2000)
▶
NEUROMUSCULAR BLOCKING REVERSAL
BX-3000
▶
This information reflects public disclosures current as of November 20, 2023
Baudax Bio’s product pipeline will evolve over time as the products move through the drug development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Baudax Bio’s filings with the Securities and Exchange Commission, and actual results may vary materially. Baudax is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.